FDA ap­proves sec­ond in­di­ca­tion for As­traZeneca and Dai­ichi's En­her­tu in less than a week

As­traZeneca and Dai­ichi Sankyo’s an­ti­body-drug con­ju­gate En­her­tu scored its sec­ond ap­proval in less than a week, this time for a sub­set of lung can­cer pa­tients.

En­her­tu re­ceived ac­cel­er­at­ed ap­proval on Thurs­day to treat adults with un­re­sectable or metasta­t­ic non-small cell lung can­cer (NSCLC) whose tu­mors have ac­ti­vat­ing HER2 (ERBB2) mu­ta­tions, and who have al­ready re­ceived a pri­or sys­temic ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.